JMKX000197
/ Jemincare
- LARVOL DELTA
Home
Next
Prev
1 to 5
Of
5
Go to page
1
July 24, 2025
A STING agonist, JMKX000197, for the treatment of malignant pleural effusion in patients with advanced solid tumors: preliminary results of the dose escalation phase in a prospective multicenter Phase I trial [WITHDRAWN]
(ESMO 2025)
- No abstract available
Clinical • Metastases • P1 data • Pleural effusion • Oncology • Solid Tumor
April 04, 2025
A Phase Ib Study of JMKX000197 Injection in the Treatment of Malignant Pleural Effusion
(clinicaltrials.gov)
- P1 | N=30 | Recruiting | Sponsor: Jemincare | Not yet recruiting ➔ Recruiting
Enrollment open • Respiratory Diseases
December 18, 2024
A Phase Ib Study of JMKX000197 Injection in the Treatment of Malignant Pleural Effusion
(clinicaltrials.gov)
- P1 | N=30 | Not yet recruiting | Sponsor: Jemincare
New P1 trial • Respiratory Diseases
December 26, 2023
Jemincare Announces 6 Approvals of Clinical Trials for its Innovative Drugs
(BioSpace)
- "On November 28, NMPA has approved a clinical trial for JMKX003948 to treat renal cell carcinoma....On December 12, FDA has approved a clinical trial for JMKX000197 to treat BCG-unresponsive non-muscle-invasive bladder cancer, and earlier on October 19, NMPA has approved the clinical trial."
IND • New trial • Bladder Cancer • Genito-urinary Cancer • Kidney Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor
June 28, 2023
A Phase I Study of JMKX000197 Injection in the Treatment of Malignant Pleural Effusion
(clinicaltrials.gov)
- P1 | N=78 | Recruiting | Sponsor: Jemincare
New P1 trial • Respiratory Diseases • IL6
1 to 5
Of
5
Go to page
1